Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a global medical technology company whose news flow reflects its activity across anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. Company announcements frequently highlight portfolio developments, clinical research, financial performance, and governance changes, giving investors and healthcare professionals insight into how the business is evolving.
Recent Teleflex news has included leadership transitions, with the Board appointing a long-serving director as Interim President and Chief Executive Officer and naming a new Chair of the Board, as well as updates on the search for a permanent CEO. The company has also reported on strategic portfolio actions, such as agreements to sell its Original Equipment Manufacturing and Development Services business and its acute care and interventional urology segments, reflecting a shift toward a more focused organization centered on core critical care and high-acuity hospital markets.
On the operational side, Teleflex regularly issues quarterly earnings releases and outlook updates, detailing revenue by region and global product category, along with commentary on non-GAAP measures like adjusted revenue and adjusted constant currency revenue growth. Dividend declarations and share repurchase authorizations are also communicated through press releases and associated SEC filings.
For those following clinical and product developments, Teleflex news covers topics such as the launch of the Barrigel™ rectal spacer in new markets and support for investigator-initiated trials like the DUBSTENT DIABETES study in interventional cardiology. Visitors to this TFX news page can review these updates in one place to understand how Teleflex’s strategy, portfolio, and financial profile are changing over time.
Teleflex (NYSE: TFX) announced that its UroLift® System won a Bronze Award for 'Best New Branded Television Campaign' and an Honorable Mention for 'Best Branded Website' at the DTC National Advertising Awards. The successful 25-week campaign highlighted lower urinary tract symptoms related to benign prostatic hyperplasia (BPH) and resulted in a 146% increase in website traffic. This recognition showcases Teleflex's creativity in a competitive space dominated by larger pharmaceutical companies.
Teleflex Incorporated (NYSE: TFX) announced a quarterly cash dividend of $0.34 per share, payable on December 15, 2021, to shareholders recorded by close of business on November 15, 2021. This move reflects the company's commitment to delivering value to its shareholders. Teleflex is a global provider of medical technologies, focusing on improving health and quality of life through innovative solutions in various medical fields. For more details, visit teleflex.com.
Teleflex reported strong financial results for Q3 2021, with revenues of $700.3 million, reflecting an 11.5% year-over-year increase. GAAP diluted EPS rose to $4.20, up from $2.46 a year prior, while adjusted diluted EPS reached $3.51, a 26.7% increase. Despite these positive results, the company lowered its revenue growth guidance due to COVID-19 impacts, now projecting 10-11% GAAP revenue growth and 8-9% constant currency growth. CEO Liam Kelly noted challenges, particularly for the UroLift product line, but emphasized the benefits of a diversified product portfolio.
Teleflex (NYSE: TFX) has completed patient enrollment in a clinical study assessing the QuikClot Control+® Hemostatic Device for mild to moderate bleeding during cardiac surgeries. The study, which aimed to measure hemostasis rates, enrolled 231 patients across seven sites, finishing three months ahead of schedule. Principal investigators express optimism about sharing findings related to various cardiac procedures. The QuikClot Control+® is FDA-cleared for severe bleeding but is investigational in this study, with plans for a 510(k) filing upon analysis completion.
Teleflex Incorporated (NYSE: TFX) will host a conference call to discuss its third quarter financial results on October 28, 2021, at 8:00 a.m. Eastern Time. Interested parties can register for the call via a provided link, which will also allow access to a live audio webcast on the company's website. An audio replay will be available following the call. Teleflex is a global provider of medical technologies, focusing on innovation to meet clinical needs and improve healthcare outcomes.
Teleflex announced new data at the American Urological Association meeting indicating that the UroLift System has the lowest rate of return procedures among treatments for benign prostatic hyperplasia (BPH). The study compared outcomes of UroLift with TURP, GreenLight, and Rezūm using data from U.S. Medicare and commercial claims from 2015 to 2019, which included over 35,000 patients. The findings highlight that while surgical retreatment rates are similar between UroLift, TURP, and GreenLight, Rezūm showed a significantly higher rate of surgical retreatment, positioning UroLift as a preferred option for BPH treatment.
On September 9, 2021, Teleflex announced the launch of two innovative products for the UroLift System: the UroLift Advanced Tissue Control (ATC) System and the UroLift 2 System. These products enhance treatment for benign prostatic hyperplasia (BPH) and will be showcased at the AUA Annual Meeting. The UroLift ATC features an improved delivery device for easier treatment, while the UroLift 2 System offers enhancements for user confidence. Data presented at the meeting will demonstrate the efficacy and safety of UroLift procedures, crucial for BPH management in men 45 and older.
Teleflex Incorporated (NYSE: TFX) will have Chairman, President, and CEO Liam Kelly speaking at the Morgan Stanley 19th Annual Global Healthcare Conference on September 15, 2021, at 8:00 a.m. ET. The event will feature a live audio webcast and a slide presentation available on Teleflex's investor website.
Teleflex is dedicated to improving healthcare through innovative medical technologies across various fields, including vascular access and emergency medicine. For more details, visit teleflex.com.
Teleflex Incorporated (NYSE: TFX) announced the publication of clinical data for the UroLift® System in the peer-reviewed journal Prostate Cancer and Prostatic Disease. The study highlights the system's efficacy in treating benign prostatic hyperplasia (BPH) and revealed long-term stability and low complication rates. Data from over 770,000 UroLift devices showed minimal breakage (0.004%) and encrustation (0.006%). The procedure offers rapid relief without common issues found in previous treatments, benefiting over 250,000 patients globally. The research asserts UroLift's superior durability and patient experience, promising a sustainable solution for BPH.
Teleflex's CEO, Liam Kelly, will address the Wells Fargo 2021 Virtual Healthcare Conference on September 9, 2021, at 12:40 PM (ET). A live audio webcast along with a slide presentation will be accessible through the Teleflex investor section website. The company specializes in medical technologies aimed at enhancing health and quality of life, with a diverse portfolio in areas such as vascular access, interventional cardiology, and emergency medicine. For more information, visit teleflex.com.